| Bid | 10.22 |
| Market Cap | 1.41B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.42 |
| PE Ratio (ttm) | -2.98 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.8 |
| Volume | 1,579,724 |
| Avg. Volume (20D) | 2,101,381 |
| Open | 10.43 |
| Previous Close | 10.52 |
| Day's Range | 9.92 - 10.95 |
| 52-Week Range | 6.56 - 14.45 |
| Beta | undefined |
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus....
Analyst Forecast
According to 6 analyst ratings, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 95.98% from the latest price.
Next Earnings Release
Analysts project revenue of $9.37M, reflecting a -44.18% YoY shrinking and earnings per share of -0.87, making a 1.16% increase YoY.
2 months ago · seekingalpha.com
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay OffVIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and...
